Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code. Applications appropriate for this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.

Eligibility

  • Higher Education Institutions both public and private
  • Nonprofits Other Than Institutions of Higher Education
  • For-Profit Organizations(small business)
  • Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply
  • Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
  • Foreign components, as defined in the NIH Grants Policy Statement, are allowed to apply
  • Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.
  • Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Funder: National Institute of Health (NIH)

URL: https://grants.nih.gov/grants/guide/pa-files/PAR-21-069.html

Deadline: October 16th 2021.